Payment overview · 2025
General Payments
$8,419.29
174 reported records · 28 companies
Healthcare provider profile · identity verified
Marla B Morgan, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BIRMINGHAM, AL · NPI 1003848821
Verified facts
What the public records show
CMS Open Payments records show Marla B Morgan, MD received $8,419.29 in general payments during 2025 across 174 reported records.
Alexion Pharmaceuticals, Inc. accounted for 53.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Fycompa, Nurtec Odt, Qulipta, Ubrelvy, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ubrelvy by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Soliris by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Fycompa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zeposia by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mayzent by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,508.22 | 53.5% | 15 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $379.97 | 4.5% | 11 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $346.52 | 4.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $340.47 | 4.0% | 17 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $305.95 | 3.6% | 11 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $300.78 | 3.6% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $283.63 | 3.4% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $277.30 | 3.3% | 14 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$220.17 | 2.6% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.79 | 2.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $158.71 | 1.9% | 8 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $136.28 | 1.6% | 10 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $115.76 | 1.4% | 3 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $111.11 | 1.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $100.05 | 1.2% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $99.93 | 1.2% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $98.39 | 1.2% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.89 | 1.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.06 | 1.0% | 5 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $63.18 | 0.8% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $38.11 | 0.5% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $36.49 | 0.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.67 | 0.3% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $23.66 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.74 | 0.2% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $18.71 | 0.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.90 | 0.2% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$14.85 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,926.10 | 164 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,465.00 | 2 |
| Travel and Lodging | $1,783.30 | 5 |
| Consulting Fee | $150.00 | 1 |
| Education | $94.89 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $1,537.45 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $379.97 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $346.52 | 11 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $305.95 | 11 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $283.63 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $238.81 | 13 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $220.17 | 10 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $205.79 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $195.82 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $195.82 | 10 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $188.30 | 8 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $155.95 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $152.17 | 9 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $142.97 | 7 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $136.28 | 10 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $115.76 | 3 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $111.11 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $101.44 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $100.05 | 5 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $99.93 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $87.89 | 4 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $87.38 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $83.06 | 5 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $81.48 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $63.18 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $60.87 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $51.09 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $38.11 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $27.67 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 33 | exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 60 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 54 | exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 207 | 69 |
| Levetiracetam | Levetiracetam | 152 | 53 |
| Gabapentin | Gabapentin | 145 | 44 |
| Memantine Hcl | Memantine Hcl | 143 | 44 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 138 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 97 | 36 |
| Pregabalin | Pregabalin | 97 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 32 |
| Baclofen | Baclofen | 83 | 22 |
| Primidone | Primidone | 69 | 17 |
| Topiramate | Topiramate | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 24 |
| Nurtec Odt | Rimegepant Sulfate | 60 | 13 |
| Ubrelvy | Ubrogepant | 54 | 12 |
| Lacosamide | Lacosamide | 53 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 16 |
| Rivastigmine | Rivastigmine | 53 | 15 |
| Memantine Hcl Er | Memantine Hcl | 44 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 11 |
| Oxcarbazepine | Oxcarbazepine | 41 | 11 |
| Lamotrigine | Lamotrigine | 36 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Botox | Onabotulinumtoxina | 33 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 32 | suppressed |
| Fingolimod | Fingolimod Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Topiramate Er | Topiramate | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Levetiracetam Er | Levetiracetam | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Mayzent | Siponimod | 19 | suppressed |
| Qulipta | Atogepant | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Fycompa | Perampanel | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Soliris | Eculizumab | 12 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 12 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 11 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,419.29 · 174 records | Alexion Pharmaceuticals, Inc. | BOTOX, BRIUMVI, Briviact, FYCOMPA, Gamunex-C, HYQVIA, Hizentra, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, Nayzilam, Ocrevus Zunovo, PANZYGA, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, ZAVZPRET, ZEPOSIA, ZTLido, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error